Pathology News
admin

About admin@pathologynews.com

This author has not yet filled in any details.
So far admin@pathologynews.com has created 1088 blog entries.

December 2024

Owkin Unveils New Insights into the Opportunities and Challenges for Digital Pathology and AI Solutions in Healthcare

2024-12-18T11:50:26+00:00

Owkin, the first end-to-end AI-biotech that uses cutting-edge AI to unlock precision drug discovery, development, and diagnostics, has launched its latest report, State of the Nation: Opportunities and Challenges for Digital Pathology and AI Solutions, exploring the evolving landscape of digital pathology and AI in healthcare across the United States, United Kingdom, and France.

Owkin Unveils New Insights into the Opportunities and Challenges for Digital Pathology and AI Solutions in Healthcare2024-12-18T11:50:26+00:00

PathAI Launches AIM-IHC Breast Panel on AISight® Platform to Streamline Breast Cancer Biomarker Quantification and Improve Pathologist Efficiency

2024-12-16T17:12:41+00:00

PathAI, a leader in AI-powered pathology solutions, today announced the launch of the AIM-IHC Breast Panel, a set pf advanced AI-assisted, algorithms designed to quantify critical breast cancer biomarkers—HER2, ER, PR, and Ki-67. Available now on the AISight® Image Management System (IMS), this comprehensive panel provides partners with accurate, consistent scoring, enhancing precision and streamlining workflow efficiency.

PathAI Launches AIM-IHC Breast Panel on AISight® Platform to Streamline Breast Cancer Biomarker Quantification and Improve Pathologist Efficiency2024-12-16T17:12:41+00:00

Case Study: Leveraging AI for Quantitative Assessments of Kidney Health in Diabetic Animal Models

2024-12-16T15:07:19+00:00

Diabetes is a chronic condition that significantly impacts kidney health, often leading to a serious complication known as diabetic nephropathy. Over time, high blood sugar levels can damage the blood vessels in the kidneys, impairing their ability to filter waste from the blood effectively. This progressive kidney damage can result in proteinuria, decreased kidney function, and eventually, end-stage renal disease (ESRD), necessitating kidney transplantation or dialysis. Understanding the effects of diabetes on kidney health is crucial for developing effective treatments and preventive strategies to mitigate these adverse outcomes and improve the quality of life for diabetic patients.

Case Study: Leveraging AI for Quantitative Assessments of Kidney Health in Diabetic Animal Models2024-12-16T15:07:19+00:00

ZEISS and Mindpeak Partner to Advance Multiplex Immunofluorescence (mIF) Solutions for Pathology

2024-12-13T14:21:31+00:00

ZEISS partners with Mindpeak, a pioneer in AI-powered pathology solutions, to develop an integrated Multiplex Immunofluorescence (mIF) solution that serves pathologists across research, diagnostics, and clinical applications.

ZEISS and Mindpeak Partner to Advance Multiplex Immunofluorescence (mIF) Solutions for Pathology2024-12-13T14:21:31+00:00

The Institute of Tissue Medicine of the University of Bern Chooses Indica Labs’ HALO AP® to Become the First Public Health Institute in Switzerland to Deploy Digital Pathology for Diagnostics in the Cloud with Amazon Web Services (AWS)

2024-12-13T12:29:05+00:00

Indica Labs, the global leader in AI-powered digital pathology, today announces that the Institute of Tissue Medicine and Pathology at the University of Bern, a leading university based pathology institute in Switzerland, has selected HALO AP® for the Institute’s first-in-country digital pathology deployment in the cloud powered by Amazon Web Services, Inc. (AWS). The Institute selected Indica Labs for its ability to provide dependable, pathologist-centered software and AI in a powerful and highly flexible platform.

The Institute of Tissue Medicine of the University of Bern Chooses Indica Labs’ HALO AP® to Become the First Public Health Institute in Switzerland to Deploy Digital Pathology for Diagnostics in the Cloud with Amazon Web Services (AWS)2024-12-13T12:29:05+00:00

AIVIS Partners with Philips Korea to Advance AI-Driven Pathology Diagnostics

2025-06-03T12:25:33+00:00

AIVIS Inc., a leading South Korean developer of AI-powered pathology solutions, has entered into a license agreement with Philips Korea, a global healthcare technology company, to integrate its biomarker quantification software, Qanti IHC, with Philips’ digital pathology platform.

AIVIS Partners with Philips Korea to Advance AI-Driven Pathology Diagnostics2025-06-03T12:25:33+00:00

Pathologists Worldwide Join Forces to Tackle Mitotic Figure Classification: Insights From the 1000 Mitoses Project

2025-06-26T16:00:05+00:00

The identification and classification of mitotic figures are critical for the diagnosis and grading of tumors. However, pathologists often face challenges in obtaining consistent results. The 1000 Mitoses Project, an international collaborative study aimed at setting new standards for mitotic figure classification, brought together pathologists from around the globe to create a consensus-based approach.

Pathologists Worldwide Join Forces to Tackle Mitotic Figure Classification: Insights From the 1000 Mitoses Project2025-06-26T16:00:05+00:00

Clinical Insights: Quantifying the Value of AI-Powered Digital Workflows in Real-World Diagnostic Laboratories

2026-10-06T08:45:40+00:00

In this roundtable discussion, pathologists Dr. Monroe and Dr. Laser provide an overview of RNAscope technology and how it is shaping the molecular in situ hybridization (ISH) testing landscape. Attendees will see how RNAscope RNA ISH, coupled with automation capability on the BOND platform, takes ISH to the next level.

Clinical Insights: Quantifying the Value of AI-Powered Digital Workflows in Real-World Diagnostic Laboratories2026-10-06T08:45:40+00:00

How Mapping the Spatial Biology of the Tumor Microenvironment Can Benefit Cancer Drug Discovery and Development

2026-10-06T07:41:16+00:00

Comprehensive spatial analysis of the tumor microenvironment (TME) of cancer patient samples has huge potential to reveal the cellular and molecular mechanisms of disease or resistance and, ultimately, point to putative drug targets for therapeutic development.

How Mapping the Spatial Biology of the Tumor Microenvironment Can Benefit Cancer Drug Discovery and Development2026-10-06T07:41:16+00:00

CB Insights Recognizes Proscia Among Most Promising Digital Health Companies Of 2024

2024-12-06T13:35:35+00:00

CB Insights named Proscia®, a global leader in AI-enabled pathology solutions for precision medicine, to its 2024 Digital Health 50 list of the world’s most innovative private digital health companies. Proscia is also ranked as the top vendor in CB Insights’ ‘Digital pathology – general diagnostics’ and ‘Digital pathology – oncology diagnostics’ Execution, Strength, and Positioning (ESP) market matrices.

CB Insights Recognizes Proscia Among Most Promising Digital Health Companies Of 20242024-12-06T13:35:35+00:00
Legal

Bioincyte Ltd is registered in the United Kingdom
under company number 13037659

Get in touch

© Copyright 2025, Bioincyte Ltd

Fields marked with an asterisk (*) are required.
By submitting you agree to our T&C and Privacy Policy

Go to Top